9/2/2008 11:08:27 AM
PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular, Inc. initiates a federally-funded program to discover new drugs to combat influenza infection. Sponsored by the National Institute of Allergy and Infectious Diseases, Integral Molecular’s R&D program will utilize its proprietary Lipoparticle technology to discover new ways of inhibiting M2, a critical viral ion channel. The M2 ion channel is a validated drug target for all strains of influenza, including the most dangerous H5N1 pandemic strains. Each year, influenza is responsible for 3 to 5 million cases of severe illness and up to 500,000 deaths.
comments powered by